The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC. | COM | 00287Y109 | 651 | 10,000 | SH | SOLE | 10,000 | 0 | 0 | ||
| ADVAXIS INC | COM NEW | 007624208 | 2,771 | 339,180 | SH | SOLE | 339,180 | 0 | 0 | ||
| APRICUS BIOSCIENCES INC | COM NEW | 03832V307 | 3,055 | 1,447,906 | SH | SOLE | 1,447,906 | 0 | 0 | ||
| AVEO PHARMACEUTICALS INC | COM | 053588109 | 598 | 1,013,616 | SH | SOLE | 1,013,616 | 0 | 0 | ||
| BIOGEN INC | COM | 09062X103 | 84,760 | 310,000 | SH | SOLE | 310,000 | 0 | 0 | ||
| BIOVERATIV INC | COM | 09075E100 | 8,441 | 155,000 | SH | SOLE | 155,000 | 0 | 0 | ||
| INNOVIVA INC | COM | 45781M101 | 47,367 | 3,425,000 | SH | SOLE | 3,425,000 | 0 | 0 | ||
| INTRA CELLULAR THERAPIES INC | COM | 46116X101 | 5,850 | 360,000 | SH | SOLE | 360,000 | 0 | 0 | ||
| MEDICINES CO | COM | 584688105 | 85,672 | 1,752,000 | SH | SOLE | 1,752,000 | 0 | 0 | ||
| NOVELION THERAPEUTICS INC | COM NEW | 67001K202 | 11,008 | 1,025,000 | SH | SOLE | 1,025,000 | 0 | 0 | ||
| VIVUS INC | COM | 928551100 | 2,882 | 2,573,943 | SH | SOLE | 2,573,943 | 0 | 0 | ||